ScoreWhy is Inhibrx Biosciences, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -16.00% and Operating profit at -1.55% over the last 5 years
- The company is Net-Debt Free
2
The company has declared negative results in Mar'2026 after 3 consecutive positive quarters
- ROCE(HY) Lowest at -354.69%
- DEBT-EQUITY RATIO (HY) Highest at -91.47 %
- INTEREST(Q) Highest at USD 3.51 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 343.33%, its profits have risen by 58%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -0.81% over the previous quarter and currently hold 11.04% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-16.00%
EBIT Growth (5y)
-1.55%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
106.71
EV to EBIT
-6.16
EV to EBITDA
-6.27
EV to Capital Employed
-62.33
EV to Sales
639.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1752.22%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -131.92 MM
NET PROFIT(HY)
Higher at USD -66.28 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 6.5 times
-12What is not working for the Company
ROCE(HY)
Lowest at -354.69%
DEBT-EQUITY RATIO
(HY)
Highest at -91.47 %
INTEREST(Q)
Highest at USD 3.51 MM
Here's what is working for Inhibrx Biosciences, Inc.
Operating Cash Flow
Highest at USD -131.92 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -66.28 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 6.5 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Inhibrx Biosciences, Inc.
Interest
Highest at USD 3.51 MM
in the last five periods and Increased by 10.17% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -91.47 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
